Evaluation of the usefulness of anti-cholinergic and B(Beta)3 agonist in patients with OAB. - Search of the clinical efficacy and safety for the Overactive bladder patients Received by imidafenacin and mirabegron as Therapeutic agents (SORT Study)

Clinical Research Support Center Kyushu0 个研究点目标入组 400 人开始时间: 2012年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients who has contraindication of Imidafenacin 2)Patients who has contraindication of Mirabegron 3)Patients with urinary flow decreased 4)Patients with history of urinary retention 5)Patients with arrhythmia 6)Patients with hypokalemia 7)Patients with serious kidney dysfunction 8)Residual urine volume is more than 100mL 9)Patients with bladder cancer, urinary tract stones, symptomatic urinary tract infection, recurrent urinary tract infection and interstitial cystitis. 10)Patients with polyuria 11)Patients who have administered prohibited substances or done prohibited therapy within the 4 weeks before enrollment 12)Patients who have a urology or genital surgery within the 6 months before enrollment 13)Patients with history of resistance to anti-holinergic agents 14)Lower urinary tract symptoms aren't stable. 15)Any other patients who are regarded as unsuitable for this study by the investigator

发起方

Clinical Research Support Center Kyushu